1. Clinical symptoms and neutropenia: the balance of neutrophil development, functional activity, and cell death

   • Taco W. Kuijpers

   Original Paper Pages: S75 - S82

2. Granulocyte colony-stimulating factor in glycogen storage disease type 1b. Results of the European Study on Glycogen Storage Disease Type 1

   • Gepke Visser
   • Jan Rake
   • Peter G. Smit

   Original Paper Pages: S83 - S87

3. The muscle-bone relationship: methods and management – perspectives in glycogen storage disease

   • Eckhard Schönau
   • Bernd Schwahn
   • Frank Rauch

   Original Paper Pages: S50 - S52

4. Type I glycogen storage disease: favourable outcome on a strict management regimen avoiding increased lactate production during childhood and adolescence

   • Gerhard Däublin
   • Bernd Schwahn
   • Udo Wendel

   Original Paper Pages: S40 - S45

5. Disturbed lipid metabolism in glycogen storage disease type 1

   • Robert H. Bandsma
   • Peter G. Smit
   • Folkert Kuipers

   Original Paper Pages: S65 - S69

6. More questions: 10 years later

   • Ann Phillips

   Original Paper Pages: S102 - S105

7. Contraception and pregnancy in women affected by glycogen storage diseases

   • Valérie Mairovitz
   • Philippe Labrune
   • René Frydman

   Original Paper Pages: S97 - S101

8. Consensus guidelines for management of glycogen storage disease type 1b – European Study on Glycogen Storage Disease Type 1

   • Gepke Visser
   • Jan Rake
   • Peter G. Smit

   Original Paper Pages: S120 - S123

9. Glycogen storage disease type I: indications for liver and/or kidney transplantation

   • Philippe Labrune

   Original Paper Pages: S53 - S55

10. Association of glycogen storage disease 1b and Crohn disease: results of a North American survey

    • Brian K. Dieckgraefe
    • Joshua R. Korzenik
    • Lisa Dieruf

    Original Paper Pages: S88 - S92

11. Glycogen storage disease type I: pathophysiology of liver adenomas

    • Philip Lee

    Original Paper Pages: S46 - S49

12. Radical trapping in glycogen storage disease 1a

    • Birgit Wittenstein
    • Marcus Klein
    • Alfried Kohlschütter

    Original Paper Pages: S70 - S74

13. Enzyme therapy for Pompe disease: from science to industrial enterprise

    • Arnold J. Reuser
    • Hannerieke Van den Hout
    • Ans T. Van der Ploeg

    Original Paper Pages: S106 - S111

14. Effect of continuous glucose therapy with uncooked cornstarch on the long-term clinical course of type 1a glycogen storage disease

    • David A. Weinstein
    • Joseph I. Wolfsdorf

    Original Paper Pages: S35 - S39

15. Is glycogen storage disease 1a associated with atherosclerosis?

    • Froukje L. Ubels
    • Jan Rake
    • Andries J. Smit

    Original Paper Pages: S62 - S64

16. Adenovirus-mediated gene therapy in a mouse model of glycogen storage disease type 1a

    • Janice Chou
    • Adriana Zingone
    • Chi-Jiunn Pan

    Original Paper Pages: S56 - S61

17. Severe pulmonary arterial hypertension in type 1 glycogen storage disease

    • Marc Humbert
    • Philippe Labrune
    • Gérald Simonneau

    Original Paper Pages: S93 - S96

18. Glycogen storage disease type I: diagnosis and phenotype/genotype correlation

    • Dietrich Matern
    • Hans Seydewitz
    • Yuan-Tsong Chen

    Original Paper Pages: S10 - S19

19. Guidelines for management of glycogen storage disease type I – European Study on Glycogen Storage Disease Type I (ESGSD I)

    • Jan Rake
    • Gepke Visser
    • Peter G. Smit

    Original Paper Pages: S112 - S119

20. Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I)

    • Jan Rake
    • Gepke Visser
    • Peter G. Smit

    Original Paper Pages: S20 - S34

21. Historical highlights and unsolved problems in glycogen storage disease type 1

    • Shimon W. Moses

    Original Paper Pages: S2 - S9